We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

N4P N4 Pharma Plc

0.00 (0.00%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
N4 Pharma Plc N4P London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.525 08:00:15
Open Price Low Price High Price Close Price Previous Close
0.525 0.525 0.525 0.525 0.525
more quote information »
Industry Sector

N4 Pharma N4P Dividends History

No dividends issued between 22 Jun 2014 and 22 Jun 2024

Top Dividend Posts

Top Posts
Posted at 18/4/2024 07:09 by jakleeds
18 April 2024
N4 Pharma plc
("N4 Pharma" or the "Company")

Oral Delivery Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its ongoing oral delivery research work.

The Company, through its research program with the University of Queensland, has undertaken further testing, in vivo, to show the successful delivery of a Nuvec® capsule into the intestine where it has released its plasmid DNA payload to produce localised protein expression. This work further demonstrates the potential of Nuvec® as an oral delivery system for multiple nucleotide payloads.

Specifically, in this experiment an enterically coated capsule containing PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. Protein expression was significantly higher than control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In addition, a significantly higher ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec® sample compared to control.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"This work once more clearly shows that Nuvec® has the potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential applications such as a vaccination with plasmid DNA or to deliver a local product for Irritable Bowel Disease or to treat colonic cancer among many possible examples.

"We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application and further news on this will be announced when a program is identified. In the meantime, the University of Queensland will continue its work as part of our ARC funded grant with them."

For more information please contact:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director

Engage with us directly at N4 Pharma Investor Hub
Posted at 23/2/2024 07:22 by nobbygnome
Pharma/biotech don’t take risks. The chances are they will wait for all the pre clinical work to be completed before they even contemplate a deal. Just imagine the poor guy who advocates signing the deal….and then it fails in a tox study. He will have serious egg on his face and his career will be blighted.

N4P is desperate for cash and there really is no rush for Pharma to do a deal. Just wait for the N4P price to slump as another fund raise comes along…
Posted at 19/2/2024 10:47 by nobbygnome
I guess I have to apologise to Fydo for being correct over the last 5 or 6 years. Right from the start when I highlighted the issues with the Viagra extended dose form of the drug you slated me but like just about everything else N4P have touched it failed! Ho hum….
Posted at 19/2/2024 08:08 by nobbygnome
>> featherby

But understanding the science is critical to knowing whether N4P is a good investment or not!!

And although as always I will judge the evidence as it appears, I doubt very much I will ever be buying N4P. I have severe doubts the technology will work in humans…
Posted at 19/2/2024 07:24 by nobbygnome
>> Fydo

Using my PhD in immunology and 28 years of experience in the Pharma industry, I comment on the many issues with Nuvec and N4P more generally. If you want to have a debate about the science please go ahead!

I remember about 5 years ago after Nigel had a trip to Japan Dave was getting excited about the imminent commercialisation of Nuvec. Here we are in 2024 and it hasn’t even been put in a human yet!
Posted at 15/2/2024 07:20 by jakleeds
15 February 2024
N4 Pharma plc
("N4 Pharma" or the "Company")

in-vitro siRNA update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further encouraging update on its ongoing in vitro siRNA research work.

The Company has now completed its in-vitro experiments combining EGFR (epidermal growth factor receptor) and PLK1 (Polo Like Kinase 1) siRNA molecules onto the same Nuvec® nanoparticle and testing it in PC9 lung cancer cells.

The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle.

Specifically, when cells were treated with the highest dose of 75nanomolars (nm) of single loaded EGFR siRNA, cell viability after 48 hours dropped to 38%. When cells were treated with 75nm of single loaded PLK1 siRNA cell viability dropped to 33%, yet when 75nm of EGFR and PLK1 were combined together cell viability dropped to 19%.

The cellular inhibition effect increases over time up to 48 hours and increases with the amount of siRNA applied. The experiments were carried out a number of times showing a consistent effect.

The Company will now expand this work by testing knockdown of EGFR alongside BRD4 (Bromodomain-containing-protein 4) and extend the EGFR/PLK1 data in a different cell line.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"The work we are doing on multiple loading of siRNA onto one nanoparticle is extremely encouraging and is showcasing the versatility of our Nuvec® delivery system.

"This ability to be able to knockdown two independent pathways leading to a positive added impact is an innovative approach in developing novel cancer treatments aimed at reducing the ability for tumour escape. We will continue to present this data to potential licensing partners as all this work strengthens the potential for collaboration opportunities."
Posted at 19/1/2024 08:00 by jakleeds
19 January 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

Patent Grant

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec(R) in India.

The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China .

Nigel Theobald, Chief Executive Officer of the Company, commented:

"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec(R)."

For more information please contact:
Posted at 08/1/2024 15:12 by nobbygnome
Hmmmm Fydo’s first post since October 2019 and as far as I can see he has never posted on N4P before. Who has tipped him the wink….
Posted at 25/7/2023 08:13 by tomboyb
25/07/2023 7:00am
UK Regulatory (RNS & others)

N4 Pharma (LSE:N4P)
Intraday Stock Chart

Tuesday 25 July 2023

Click Here for more N4 Pharma Charts.

RNS Number : 0209H

N4 Pharma PLC

25 July 2023

25 July 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

Patent Grant and Board Change

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces two operational updates.

Granting of further US patent

The University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its further patent application in relation to Nuvec(R) in the United States.

N4 Pharma has licensed the exclusive worldwide rights to Nuvec(R) from the University of Queensland for therapeutic uses in humans and animals.

This granted patent in the US is for the composition of matter of the nanoparticle itself and will sit alongside the first US patent grant announced on 31 January 2022, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the Company.

Board Change

The Company announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023.

The Company will initiate a search process to identify an additional Non-Executive Director and will provide an update as and when appropriate.

Nigel Theobald, Chief Executive Officer of the Company, commented:

" We are delighted to receive notification of this further patent grant for our licensed patent in this critical and influential market.

"The granting of this patent now means the patents in the US are on equal terms to those granted in other territories for both the particle itself and how it is made.

"On behalf of the Board, I would like to thank John f
Posted at 25/7/2023 08:04 by earwacks
USA patent news update is very welcome strengthening of intellectual property. Research in America is funded a thousand times more in this area. So when does the money runnout? That is the beauty of N4, there are no expensive lab costs they license or lend at the moment the nano technology to the drug companies. At some stage it will become an industry standard in the treatment of cancers and delivery of vaccinations. Looks like we are still ahead of the game in this area and the professor at Queens uni in Australia who are partners has been awarded a grant to further research at no cost to N4p. The hard miles have been done in establishing the technology property and establishing up to date world wide patents.

Your Recent History

Delayed Upgrade Clock